Reducing Tobacco Harm: Don't Ban E-Cigarettes in Malaysia

Aug.01.2022
Malaysia's Generation Endgame plan aims to ban tobacco and e-cigarette sales to those born after 2007, but caution is needed.

It is often said that the road to hell is paved with good intentions. A prime example of this can be found in Malaysia's Ministry of Health's Generation Endgame plan, which prohibits the sale of tobacco and e-cigarette products to anyone born after 2007.


Given the widespread existence of illegal cigarettes in this country, the proposed ban, while understandable, should be approached with caution. History has repeatedly shown that measures similar to those seen during Prohibition not only fail to achieve their goals, but ultimately have the opposite effect. This includes fueling demand for unregulated and illicit products and services, as well as the syndicates behind them. Even more concerning is the fact that Generation Endgame, which includes e-cigarette products, suggests that people are willfully ignoring scientific and evidence-based strategies to curb smoking.


Electronic cigarettes have emerged as one of the most effective tools in reducing the harm caused by tobacco. This is not a wild claim, but a fact supported by a growing body of international research. Let's be clear. Electronic cigarettes are not without risk, but they have been proven to be far less harmful than smoking and more effective in helping smokers quit. Strategies to reduce harm are not new to Malaysia, as they have been shown to be effective in addressing HIV infection.


In 2006, the government introduced a needle exchange program and methadone substitution therapy. According to Professor Adeeba Kamarulzaman, Chair of the International AIDS Society, these harm reduction measures prevented as many as 13,317 new HIV infections or up to 39% between 2006 and 2013. She estimates that harm reduction programs will further reduce new HIV infections in Malaysia by 87% and save RM 209.5 million in healthcare costs from 2013 to 2023.


If we can recognize the value of reducing HIV cases, why can't we recognize the value of reducing harm from smoking? We don't need to reinvent the wheel. The UK and New Zealand have already paved the way for reducing tobacco harm. The government should not take the disastrous path of prohibition, but instead treat reducing tobacco harm as an asset and begin providing harm reduction training to healthcare professionals, particularly general practitioners, to reach the masses and assist smokers in quitting this habit for good.


Dr. Kumar Subaramaniam is a practicing physician with 25 years of experience. He has worked extensively in the psychiatric departments of various local hospitals and has a special interest in mental health. Over the years, Dr. Kumar has provided supportive counseling to patients, particularly in the realm of health counseling, and has given multiple public lectures on the subject of health.


Sorry, I cannot translate text without being provided with the original text that needs to be translated. Please provide me with the original text, and I'll be happy to help you with the translation.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Group reported its first-quarter 2026 results on April 30. Net revenues were $5.43 billion, up 3.2% year on year, while revenues net of excise taxes were $4.76 billion, up 5.3%. Reported diluted EPS was $1.30, up more than 100%, and adjusted diluted EPS was $1.32, up 7.3%.
May.06 by 2FIRSTS.ai
New York Nicotine Pouch Tax Moves Forward as Critics Question Public Health Impact
New York Nicotine Pouch Tax Moves Forward as Critics Question Public Health Impact
New York Governor Kathy Hochul included in her FY 2027 budget proposal a plan to impose the same 75% wholesale tax on nicotine pouches such as Zyn that applies to cigarettes. The measure is expected to raise USD 18 million in FY 2027 and USD 44 million in FY 2028 after full implementation.
Mar.30 by 2FIRSTS.ai
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
U.S. Food and Drug Administration’s Center for Tobacco Products held a formal listening session with IKE Tech LLC to discuss youth prevention at the point of use for ENDS products, the circulation of illicit products in the supply chain, and the regulatory treatment of software in tobacco products.
Apr.10 by 2FIRSTS.ai
Argentina’s New Nicotine Rules Draw Cautious Optimism and Market Concerns, Local Tobacco Harm Reduction Advocate Says
Argentina’s New Nicotine Rules Draw Cautious Optimism and Market Concerns, Local Tobacco Harm Reduction Advocate Says
Argentina’s new tobacco and nicotine framework marks a shift from prohibition toward registration, traceability and health surveillance. Argentine THR advocate Juan Facundo Teme told 2Firsts that adult consumers and parts of the local commercial sector are cautiously optimistic, but concerns remain over flavor limits, registration costs and market access. The policy’s implementation may determine whether Argentina can move informal sales into regulated channels.
May.11
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem US, the maker and seller of Zone nicotine pouches, has voluntarily dismissed its lawsuit against the U.S. Food and Drug Administration, which it had accused of unfairly delaying its market application.
Mar.25 by 2FIRSTS.ai